The ADI1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for functional studies of acireductone dioxygenase 1 (ADI1) in a human cervical adenocarcinoma background. This product offers a genetically heterogeneous loss-of-function model generated through targeted disruption of the ADI1 gene in HeLa cells, providing a versatile tool for investigating methionine metabolism and related cellular processes.
HeLa cells, an immortalized cell line derived from a cervical adenocarcinoma, harbor integrated human papillomavirus type 18 (HPV-18) sequences, leading to the inactivation of tumor suppressors p53 and Rb. This well-characterized cancer cell line is widely employed for studying oncogenic signaling, metabolic reprogramming, and stress responses, making it an ideal host for examining the consequences of ADI1 ablation in a transformed metabolic context.
ADI1 encodes a key enzyme in the methionine salvage pathway, catalyzing the conversion of acireductone to 2-keto-4-methylthiobutyrate, a critical intermediate for methionine recycling. Within this pathway, ADI1 functions downstream of methylthioadenosine (MTA) processing and interacts with MTNA and MTNB to facilitate the regeneration of methionine from methylthioribose-1-phosphate. The enzyme??s activity is modulated by oxidative stress and transition metal ions, and its disruption is expected to impair downstream methionine synthesis and methylthioadenosine recycling, thereby affecting cellular methylation potential and redox balance.
In the HeLa cellular environment, which exhibits deregulated cell cycle control and metabolic flexibility, ADI1 knockout is anticipated to heighten reliance on exogenous methionine and sensitize cells to oxidative stress. The accumulation of methionine salvage intermediates, coupled with reduced methionine availability, may compromise S-adenosylmethionine (SAM)-dependent methylation reactions and alter gene expression programs, providing a model to dissect the intersection of one-carbon metabolism and cancer cell fitness.
This polyclonal knockout population enables a range of experimental applications, including quantification of methionine salvage intermediates via LC-MS, proliferation assays under methionine-restricted conditions, global metabolite profiling, and assessment of reactive oxygen species (ROS) levels. Western blotting can be used to confirm ADI1 protein loss, while rescue experiments with exogenous methionine help validate pathway-specific phenotypes. For further details or technical support, please contact Ascent Research.
